188 related articles for article (PubMed ID: 21836029)
1. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity.
Wong F; Watson H; Gerbes A; Vilstrup H; Badalamenti S; Bernardi M; Ginès P;
Gut; 2012 Jan; 61(1):108-16. PubMed ID: 21836029
[TBL] [Abstract][Full Text] [Related]
2. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.
Wong F; Gines P; Watson H; Horsmans Y; Angeli P; Gow P; Minini P; Bernardi M
J Hepatol; 2010 Aug; 53(2):283-90. PubMed ID: 20541828
[TBL] [Abstract][Full Text] [Related]
3. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.
Ginès P; Wong F; Watson H; Milutinovic S; del Arbol LR; Olteanu D;
Hepatology; 2008 Jul; 48(1):204-13. PubMed ID: 18508290
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study.
Ginès P; Wong F; Watson H; Terg R; Bruha R; Zarski JP; Dudley F;
Aliment Pharmacol Ther; 2010 Apr; 31(8):834-45. PubMed ID: 20102356
[TBL] [Abstract][Full Text] [Related]
5. Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study.
Aronson D; Verbalis JG; Mueller M; Krum H;
Eur J Heart Fail; 2011 Mar; 13(3):327-36. PubMed ID: 21199833
[TBL] [Abstract][Full Text] [Related]
6. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.
Soupart A; Gross P; Legros JJ; Alföldi S; Annane D; Heshmati HM; Decaux G
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1154-60. PubMed ID: 17699341
[TBL] [Abstract][Full Text] [Related]
7. Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development.
Watson H; Jepsen P; Wong F; Ginès P; Córdoba J; Vilstrup H
Metab Brain Dis; 2013 Jun; 28(2):301-5. PubMed ID: 23463488
[TBL] [Abstract][Full Text] [Related]
8. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
Thuluvath PJ; Maheshwari A; Wong F; Yoo HW; Schrier RW; Parikh C; Steare S; Korula J
Aliment Pharmacol Ther; 2006 Sep; 24(6):973-82. PubMed ID: 16948809
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.
Dahl E; Gluud LL; Kimer N; Krag A
Aliment Pharmacol Ther; 2012 Oct; 36(7):619-26. PubMed ID: 22908905
[TBL] [Abstract][Full Text] [Related]
10. May vaptans contribute to the treatment of refractory ascites?
Salerno F; Cazzaniga M; Accordino S
J Hepatol; 2010 Aug; 53(2):225-7. PubMed ID: 20546963
[No Abstract] [Full Text] [Related]
11. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.
Gerbes AL; Gülberg V; Ginès P; Decaux G; Gross P; Gandjini H; Djian J;
Gastroenterology; 2003 Apr; 124(4):933-9. PubMed ID: 12671890
[TBL] [Abstract][Full Text] [Related]
12. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.
Bossen L; Krag A; Vilstrup H; Watson H; Jepsen P
Hepatology; 2016 Jun; 63(6):1968-76. PubMed ID: 26599983
[TBL] [Abstract][Full Text] [Related]
13. The management of ascites and hyponatremia in cirrhosis.
Ginès P; Cárdenas A
Semin Liver Dis; 2008 Feb; 28(1):43-58. PubMed ID: 18293276
[TBL] [Abstract][Full Text] [Related]
14. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
Cárdenas A; Ginès P; Marotta P; Czerwiec F; Oyuang J; Guevara M; Afdhal NH
J Hepatol; 2012 Mar; 56(3):571-8. PubMed ID: 22027579
[TBL] [Abstract][Full Text] [Related]
15. [Aquaretic agents].
Jiménez W
Nefrologia; 2002; 22 Suppl 5():52-5. PubMed ID: 12107918
[No Abstract] [Full Text] [Related]
16. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites.
Guyader D; Patat A; Ellis-Grosse EJ; Orczyk GP
Hepatology; 2002 Nov; 36(5):1197-205. PubMed ID: 12395330
[TBL] [Abstract][Full Text] [Related]
17. Treatment with colchicine and survival of patients with ascitic cirrhosis: a double-blind randomized trial.
Adhami JE; Basho J
Panminerva Med; 1998 Mar; 40(1):75-81. PubMed ID: 9573762
[TBL] [Abstract][Full Text] [Related]
18. Ascites and spontaneous bacterial peritonitis: an Asian perspective.
Lee JM; Han KH; Ahn SH
J Gastroenterol Hepatol; 2009 Sep; 24(9):1494-503. PubMed ID: 19743995
[TBL] [Abstract][Full Text] [Related]
19. Association of the G-protein and α2-adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the effects of diuretics in patients with cirrhosis with refractory ascites: a randomised clinical trial.
Yang YY; Lin HC; Lee WP; Chu CJ; Lin MW; Lee FY; Hou MC; Jap JS; Lee SD
Gut; 2010 Nov; 59(11):1545-53. PubMed ID: 20833658
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
Ferguson JW; Therapondos G; Newby DE; Hayes PC
Clin Sci (Lond); 2003 Jul; 105(1):1-8. PubMed ID: 12639215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
